Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) EBITDA Margin: 2021-2025

Historic EBITDA Margin for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to 5.16%.

  • Oncology Institute's EBITDA Margin rose 79000.0% to 5.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.05%, marking a year-over-year increase of 78900.0%. This contributed to the annual value of 14.47% for FY2024, which is 84000.0% up from last year.
  • As of Q3 2025, Oncology Institute's EBITDA Margin stood at 5.16%, which was up 79000.0% from 8.5% recorded in Q2 2025.
  • Oncology Institute's EBITDA Margin's 5-year high stood at 1.89% during Q2 2021, with a 5-year trough of 77.56% in Q4 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 15.86% (2023), whereas its average is 20.36%.
  • Examining YoY changes over the last 5 years, Oncology Institute's EBITDA Margin showed a top increase of 431000bps in 2022 and a maximum decrease of -296500bps in 2022.
  • Oncology Institute's EBITDA Margin (Quarter) stood at 77.56% in 2021, then skyrocketed by 56bps to 34.47% in 2022, then skyrocketed by 51bps to 16.88% in 2023, then soared by 35bps to 10.97% in 2024, then surged by 53bps to 5.16% in 2025.
  • Its last three reported values are 5.16% in Q3 2025, 8.5% for Q2 2025, and 8.52% during Q1 2025.